Briefs: Alizyme CEO steps down; Autonomy, Brady win new business; Minster Pharma’s migraine drug trial progresses
Drug developer Alizyme plc said that, as part of reconstruction, Tim McCarthy stepped down as Chief Executive Officer and resigned as a director on 3 July.
During this period of ongoing reconstruction, Alan Goodman will take charge of day to day affairs.
Mr McCarthy is a founder of the Cambridge-based company.
Mr Goodman is a non-executive director who joined the Board in April. He has founded or co-founded many biotechnology and healthcare companies over the last 25 years, including Agricultural Genetics Company, Medeva plc, Chiroscience Group plc, Acambis plc, Oxford BioMedica plc, CeNeS Pharmaceuticals plc, Core Group plc and Amura Ltd. He was Chief Executive of Acambis plc, non-executive Chairman of Oxford BioMedica plc and is currently a member of the Supervisory Board of Paion AG and Chief Executive of Avlar BioVentures Ltd.
&
Autonomy Corporation plc, a global leader in infrastructure software for the enterprise, said that Loma Linda University Health Sciences Center (LLU) has selected Autonomy's Business Process Management solution to improve its operational efficiency.
By deploying the Autonomy solution, which will include electronic forms, electronic signatures and workflows, LLU will be able to transform many of its paper-based processing of physician timesheets, expense reports, student-focused processes and patient-focused processes into an automated, electronic information processing solution.
&
Minster Pharmaceuticals plc, the drug development firm specialising in neurological and psychiatric disorders, announced the publication in The Lancet Neurology of positive results from a Phase II trial of tonabersat in the prevention of migraine with aura.
A summary of the article, and access to its full text, is available online at http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2809%2970135-8/fulltext. The article's authors believe tonabersat has a preventive effect in migraine with aura and that a further study should be conducted owing to the importance of the trial's findings. The authors conclude that the findings support the theory that auras are caused by cortical spreading depression and that CSD is not implicated in migraine attacks without aura.
&
Brady plc said that Japan's largest general trading company has signed a new contract to extend the use of Brady's trading and risk technology to include all of their global trading of both physical and derivative precious metals.
The revenue from the contract is substantial and anticipated to be recognised in the second half of this year and beyond, the company said.
